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Abstract
Background: Three distinct forms of bovine spongiform encephalopathy (BSE), defined as classical (C-), low (L-) or
high (H-) type, have been detected through ongoing active and passive surveillance systems for the disease.
The aim of the present study was to compare the ability of two sets of immunohistochemical (IHC) and Western
blot (WB) BSE confirmatory protocols to detect C- and atypical (L- and H-type) BSE forms.
Obex samples from cases of United States and Italian C-type BSE, a U.S. H-type and an Italian L-type BSE case were
tested in parallel using the two IHC sets and WB methods.
Results: The two IHC techniques proved equivalent in identifying and differentiating between C-type, L-type and
H-type BSE. The IHC protocols appeared consistent in the identification of PrP
Sc distribution and deposition
patterns in relation to the BSE type examined. Both IHC methods evidenced three distinct PrP
Sc phenotypes for
each type of BSE: prevailing granular and linear tracts pattern in the C-type; intraglial and intraneuronal deposits in
the H-type; plaques in the L-type.
Also, the two techniques gave comparable results for PrP
Sc staining intensity on the C- and L-type BSE samples,
whereas a higher amount of intraglial and intraneuronal PrP
Sc deposition on the H-type BSE case was revealed by
the method based on a stronger demasking step.
Both WB methods were consistent in identifying classical and atypical BSE forms and in differentiating the specific
PrP
Sc molecular weight and glycoform ratios of each form.
Conclusions: The study showed that the IHC and WB BSE confirmatory methods were equally able to recognize C-, L-
and H-type BSE forms and to discriminate between their different immunohistochemical and molecular phenotypes. Of
note is that for the first time one of the two sets of BSE confirmatory protocols proved effective in identifying the L-type
BSE form. This finding helps to validate the suitability of the BSE confirmatory tests for BSE surveillance currently in place.
Background
Transmissible spongiform encephalopathies (TSEs), or
prion diseases, are fatal neurological disorders in both
animals and humans. TSEs include bovine spongiform
encephalopathy (BSE) in cattle, scrapie in sheep and
goats, transmissible mink encephalopathy (TME) in
mink and Creutzfeldt-Jakob disease (CJD) in humans.
The agent of TSEs has been ascribed to an infectious
protease-resistant isoform of the normal host encoded
cellular prion protein (PrP
C), termed pathological prion
protein (PrP
Sc) [1].
BSE was first detected in the United Kingdom (UK) in
1986 [2], where the disease grew to epidemic propor-
tions in the cattle population, with approximately
184,600 cases diagnosed [3]. An estimated 3 million cat-
tle may have been infected. Worldwide, about 7,900 BSE
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Canada, Japan and the United States (U.S.) [4].
Passive and active surveillance programs were devel-
oped to monitor cattle populations for the presence of
BSE. Under passive surveillance, cattle showing clinical
symptoms consistent with BSE must be tested for the
disease. Active surveillance programs require BSE test-
ing by rapid screening tests at the abattoir of apparently
healthy cattle of a certain age and of fallen/dead stock.
A major public health concern due to its transmissibil-
ity to humans, BSE is thought to be the cause of the
fatal human prion disorder variant Creutzfeldt-Jakob
disease (vCJD) [5,6]. Besides transmission among cattle
and to humans, BSE can cross the species barrier to
other species such as small ruminants [7,8], exotic
ungulates [9], and felids [10].
The origin of BSE remains an enigma: one hypothesis
is that the disease was acquired by the cattle population
through the consumption of meat and bone meal
(MBM) derived from scrapie-affected sheep and goats or
from BSE-infected cattle [11,12]. The efficiency of MBM
feeding bans, which subsequently led to a worldwide
decline in BSE among the cattle population, supports a
food related spread of the disease.
Another hypothesis is that BSE may have arisen as a
sporadic [13,14] or genetic [15,16] disease of cattle,
which was then amplified by food-borne recycling of
MBM containing central nervous system (CNS) tissues
from BSE-infected cattle.
It was once thought that BSE was the result of a single
prion strain. The disease presented with an identical
clinical and pathological phenotype in cattle [17], with
homogenous and consistent PrP
Sc molecular features
and deposition patterns in the brainstem, independently
of the geographical origin of the BSE isolates detected
[18-21] or breed or route of inoculation in cases of
experimental transmission [22]. In transmission studies
using mouse models, the BSE strain was characterized
by similar incubation time, biochemical features, lesion
profile and PrP
Sc distribution regardless of origin
[23,24]. But as diagnostic techniques were further
refined and the BSE epidemic continued to decline, “aty-
pical” cases of the disease, mainly in older cattle, began
to be reported from around the world. The new variants
were classified as low (L-) or high (H-) type based on
differences in the molecular size of the PrP
Sc unglycosy-
lated protein band visualized on Western blot (WB)
assays as compared to classical BSE (C-type BSE) [21].
Research into more detailed characterization of PrP
Sc
deposition throughout the brain of BSE-affected cattle
uncovered the first example of atypical L-type BSE in
Italy in 2004 [25]. Two older animals were found to be
affected by a variant form of BSE, classified as L-type,
based on WB analysis demonstrating faster
electrophoretic mobility of PrP
Sc unglycosylated moiety.
WB analysis also revealed a dominant monoglycosylated
PrP
Sc glycoform profile for these two atypical cases.
Brain samples from three additional Italian BSE-affected
cattle were noted to display the same molecular features
and were subsequently confirmed as atypical L-type
cases.
Immunohistochemical analysis of brain sections
revealed differences in the distribution and features of
PrP
Sc immunoreactivity between the C-type BSE and the
Italian L-type BSE cases. Specifically, in three Italian L-
type BSE cases out of the five described so far, PrP
Sc
was found to be more abundant in the forebrain than in
the brainstem where PrP
Sc deposition was predominant
in the C-type BSE cases. Unexpectedly, PrP
Sc deposition
in three out of these five Italian L-type BSE cases
occurred in an unusual pattern referred to as amyloid
plaques, which is seldom reported in the literature for
C-type BSE [26]. Availability of only the brainstem area
for the fourth Italian L-type BSE case precluded full
characterization for PrP
Sc p l a q u e s .A tt h et i m eo ft h i s
writing, the fifth L-type BSE case was undergoing char-
acterization studies for PrP
Sc plaque deposits.
On the basis of the unique neuropathological feature
of PrP
Sc amyloid plaques, the new L-type variant was
named bovine amyloidotic spongiform encephalopathy
(BASE).
The discovery of the Italian case occurred concomi-
tantly with the detection of a second atypical BSE var-
i a n t ,t h eH - t y p e ,r e p o r t e di nF r a n c ei n2 0 0 4[ 2 7 ] .H -
type cases were characterized by a higher molecular
weight of the unglycosylated fraction of PrP
Sc than C-
type BSE and by strong labelling with P4 [28] and
12B2 [29] monoclonal antibodies. Both antibodies are
directed to an N-terminal epitope that is still present
after proteinase K (PK) cleavage of H-type BSE and
also scrapie, but not of C-type or L-type BSE-derived
PrP
Sc.
Immunohistochemical studies on the brainstem from
cases confirmed as H-type from Germany [30] and the
U.S. [16,31] showed that the prevalent PrP
Sc deposition
pattern was less intense, intraneuronal and intraglial,
unlike that of C-type BSE, which is more intense, with
mainly granular and linear tract deposition patterns. At
present, approximately 61 atypical BSE cases have been
detected worldwide [as of March 2011].
In Italy, where both active and passive surveillance
systems for BSE are in place, five out of 145 BSE cases
detected to date were identified as BASE (L-type) var-
iants. No H-type cases have been detected in Italy so
far. However, the IHC and WB BSE confirmatory proto-
cols in place in Italy (hereafter referred to as horse rad-
ish peroxidise [HRP] and whole homogenate extraction
[WHE] methods) have proved successful in identifying
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Sc deposition in H-type BSE cases from Germany
[30] and other European countries, respectively [21].
In non-European countries, and the U.S. in particular,
current BSE surveillance programs focus on “high-risk
cattle” defined as cattle displaying clinical symptoms
consistent with BSE or fallen stock. U.S. surveillance has
detected three BSE cases: one C-type and two H-type
BSE have been identified [31]. The efficacy of the U.S.
IHC and WB BSE confirmatory protocols (hereafter
referred to as alkaline phosphatase [AP] and scrapie
associated fibrils extraction [SAFE] methods, respec-
tively) to identify L-type BSE forms has not yet been
tested. The purpose of this study was to evaluate Italian
and U.S. IHC and WB BSE confirmatory protocols in
order to assess their suitability to detect C-, H- and L-
type BSE cases. Tissue samples of classical and atypical
BSE cases from Italy and the U.S., age-matched when
possible, were tested by both the IHC or the WB meth-
ods used in each of the two countries.
Results
Immunohistochemical examination
Description of the PrP
Sc deposition patterns
Nine different PrP
Sc deposition patterns for the classical
and atypical BSE cases were identified. The PrP
Sc
deposition types, as described elsewhere [32,20], were:
-p u n c t a t et y p econsisting of powdery and diffuse
PrP
Sc staining throughout the neuropil;
- granular type characterized by granular PrP
Sc accu-
mulations in the neuropil;
- coalescing type seemingly arising from the merging
of granular PrP
Sc deposits to form amorphous or mesh-
like masses;
-g l i a lt y p ewith PrP
Sc deposits branching out from
the nucleus of a glial cell on its processes, conferring it
a stellate appearance;
- intraneuronal type with fine punctate PrP
Sc immu-
noreactivity throughout the neuronal cytoplasm;
- perineuronal type consisting in thread-like PrP
Sc
deposits around individual neuronal perikarya and
neurites;
-i n t r a g l i a lt y p ewith fine, punctate PrP
Sc immunor-
eactivity adjacent to the glial nuclei;
-l i n e a rt r a c tcharacterized by PrP
Sc deposits along
neuronal processes;
- plaques consisting of dense, generally rounded accu-
mulations of PrP
Sc, unicentric or occasionally multi-
centric, that may present a pale core surrounded by a
dark border.
Comparative analysis of PrP
Sc deposition using AP and HRP
methods
C-type BSE The Italian C-type BSE (16193/02) obex tis-
sue section stained by the AP method resulted in an
overall marked intensity grade for PrP
Sc. Moderate-to-
marked punctate and granular, as well as intraneuronal
and perineuronal type PrP
Sc deposition patterns were
evident in the hypoglossal nucleus, dorsal motor nucleus
of the vagus nerve (DMNV) (Figure 1A), nucleus of the
solitary tract (NST), nucleus of the spinal tract of the
trigeminal nerve (NSTV), reticular formation and olivary
nucleus. Mild-to-marked coalescing and linear tract type
PrP
Sc deposition was present in the reticular formation.
In serial sections of the obex very similar results were
obtained with the HRP method, with no detectable dif-
ferences in PrP
Sc distribution, deposition pattern or
staining intensity (Figure 1B).
The U.S. C-type BSE case (B5330-7 D) examined
under the AP protocol contained overall moderate-to-
marked PrP
Sc immunoreactivity. There was moderate
punctate, granular, intraneural and perineuronal type
PrP
Sc deposition in all the nuclei of the obex (Figure
1C). Glial, granular and linear tract PrP
Sc deposition
patterns were mainly detected in the reticular formation.
The HRP protocol applied to serial sections of the U.
S. C-type BSE case stained with the same neuroanatomi-
cal PrP
Sc distribution as seen under the AP protocol.
Furthermore, PrP
Sc deposition patterns and related
intensity for all the target nuclei appeared similar to the
corresponding obex sections stained under the AP pro-
tocol (Figure 1D).
H-type BSE The H-type BSE case (B14842) showed
overall moderate PrP
Sc immunoreactivity when stained
Figure 1 C-type BSE. (A and B) DMNV of the Italian case (16193/
02); (C and D) NST of the U.S. case (B5330-7 D). (A and C) AP IHC
method; (B and D) HRP IHC method. Bar = 100 μm.
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Sc was mainly detected at the
level of the DMNV, NST, NSTV and the reticular for-
mation, primarily appearing as punctate and granular
deposits with areas of intraglial deposition (Figure 2A).
Intraneuronal and perineuronal PrP
Sc deposition was
present in the DMNV and the reticular formation (Fig-
ure 2C).
Serial tissue sections of the same case stained under
the HRP protocol revealed more widespread PrP
Sc dis-
tribution and moderate-to-marked immunolabelling
intensity. PrP
Sc was detected through the whole tissue
section. Interestingly, the HRP method revealed more
intraglial (Figure 2B) and intraneuronal (Figure 2D)
deposition patterns, with a higher degree of staining
intensity than the AP method.
L-type BSE The L-type BSE (BASE) (12966/07) obex
tissue sections examined under the AP protocol con-
tained mild-to-moderate PrP
Sc immunoreactivity. The
prevalent PrP
Sc deposition pattern was the punctate and
granular type, which was mildly present in the hypoglos-
sal and olivary nucleus and moderately present at the
level of the DMNV, NST, NSTV, and reticular forma-
tion. Intraneuronal type PrP
Sc deposition was identified
in some neurons of the hypoglossal nucleus, DMNV,
NSTV, reticular formation and olivary nuclei.
Perineuronal type PrP
Sc immunoreactivity of moderate
intensity was identified in the DMNV (Figure 3A), reti-
cular formation and the olivary nuclei. Linear tract type
PrP
Sc deposits were present at the level of the reticular
formation. Also present in the reticular formation were
several larger aggregates of staining or plaques ranging
from 5 to 25 μm in diameter. The majority of the pla-
ques appeared as unicentric structures, but some were
characterized by the presence of a pale core surrounded
by a dark radial periphery.
The results obtained on the serial obex tissue sections
of the BASE case stained according to the HRP method
were comparable in terms of PrP
Sc distribution, staining
intensity and deposition pattern (Figure 3B).
The frontal cortex of the BASE case stained under the
AP protocol contained moderate punctate, granular type
PrP
Sc deposition along the most superficial region of the
cortex. In the deeper regions of the gray matter, a mild
granular PrP
Sc deposition pattern was present. A similar
pattern with moderate staining intensity was present
along the transition zone between the gray and white
matter. In the white matter there were granular PrP
Sc
deposits and scattered PrP
Sc positive plaques that
appeared as dense unicentric or multicentric, dark red,
round structures (Figure 3C).
Serial tissue sections of the frontal cortex from this
animal stained using the HRP procedure revealed a
similar distribution of PrP
Sc deposits, including the
PrP
Sc pattern types described above and comparable
immunoreactivity intensity. The plaques appeared as
Figure 2 U.S. H-type BSE (B14842): reticular formation.( Aa n d
B) Intraglial PrP
Sc deposition pattern, marked by arrows; inset for
each shows higher magnification for the marked glial cells indicated
by the arrow with an asterisk. (C and D) Intraneuronal PrP
Sc
deposition pattern. (A and C) AP IHC method; (B and D) HRP IHC
method. Bar = 50 μm.
Figure 3 Italian L-type BSE (BASE) (12966/07).( Aa n dB )
Perineuronal PrP
Sc deposition pattern of the DMNV; (C and D)
Plaque-like PrP
Sc deposition pattern in the white matter of the
frontal cortex. (A and C) AP IHC method; (B and D) HRP IHC
method. Bar = 50 μm.
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which displaying a pale core surrounded by a dark radial
periphery (Figure 3D).
Western blot analysis
The obex tissue derived from a healthy bovine and used
as control for PK digestion tested negative with both
extraction methods. The WHE and SAFE extraction
methods were both able to clearly identify classical and
atypical BSE cases on subsequent WB analyses. When
the 6H4 mAb was employed, which is directed against
the protease-resistant core of the prion protein, all BSE
samples (C-, H-, L-type BSE cases) tested positive (Figure
4 A ) .I nc o n t r a s t ,w h e nt h eP 4m A bw a su s e d ,w h i c hi s
directed against the N-terminus of the protease-resistant
core of PrP, only the H-type BSE sample was recognized
(Figure 4B) by both extraction methods. The density
comparison between the signals obtained with P4 and
6H4 mAbs showed a P4/6H4 ratio of at least 1.2 for both
methods in the H-type BSE sample. These findings were
due to the different PK cleavage site for the three BSE
types, as previously described by Jacobs et al. (21).
In addition, the glycoform ratio of the different BSE
samples was determined after staining with the 6H4
mAb. As shown in Figure 5, the L- and H-type BSE
cases showed a lower proportion of the di-glycosylated
and a higher proportion of the mono-glycosylated band
than the C-type BSE cases according to both extraction
methods. Specifically, the L-type BSE exhibited an equal
or slightly inverted ratio between the mono- and the di-
glycosylated PrP isoform, which is a characteristic fea-
ture of L-type BSE (Figure 5).
Discussion and conclusions
The aim of this study was to evaluate the suitability of
IHC and WB confirmatory tests routinely used in the U.
S. and Italy for the diagnosis of classical and atypical
BSE. In contrast to C-type BSE cases, which have pro-
gressively declined worldwide after the implementation
of feed bans, atypical BSE (L- and H-type BSE) cases
have been increasingly detected since 2004, and are pos-
tulated to arise as sporadic and genetic forms of the dis-
ease [14-16]. Most likely, the incidence of atypical BSE
cases will be constant over time [14], as occurs in spora-
dic and genetic cases of human prion diseases [33]. The
existence of atypical forms of BSE will require maintain-
ing the current active surveillance systems for BSE; the
misguided proposal many countries have put forward to
progressively limit them could result in such cases being
missed. Nonetheless, the feed bans on specified risk
materials will continue to provide effective barriers for
protecting public health.
All atypical BSE cases detected worldwide so far have
been correctly identified by currently approved BSE
rapid tests [34,35]. However, it should be noted that L-
type BSE (BASE), the only BSE variant phenotypically
characterized in detail to date [25], may contain signifi-
cantly less PrP
Sc immunoreactivity in the obex region
than C-type BSE. Since the obex is the target tissue for
the diagnosis of all BSEs, it is necessary to evaluate the
sensitivity of rapid testing and confirmatory diagnostic
techniques currently in place for atypical forms. In the
future, it may be necessary to re-evaluate whether the
obex is the best tissue for detecting atypical BSE cases.
O n ea i mo ft h ep r e s e n ts t u d yw a st oa s s e s st h ee f f e c -
tiveness of the U.S. BSE confirmatory methods to detect
L-type BSE. The results indicate that the AP and SAFE
Figure 4 Western blot analysis. Healthy bovine used as negative
control (C-), U.S. H-type BSE (1), Italian C-type BSE (2), Italian L-type
BSE (3) and U.S. C-type BSE (4) samples, all examined by whole
homogenate and SAF extraction methods. 10 milligrams of tissue
equivalent were loaded per lane. All samples were proteinase K
treated. Blots were probed with mAbs 6H4 (A) and P4 (B),
respectively.
Figure 5 Glycoform analysis. Graphic representation of the
proportions of the three PrP
Sc glycoforms of the samples examined
by the whole homogenate and the SAF extraction methods.
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tify the presence of PrP
Sc in the L-type atypical BSE
forms. The efficacy of the AP and SAFE confirmatory
methods to detect C- and H-type BSE has already been
shown [16,31].
When the AP protocol was applied to obex and fron-
tal cortex tissue sections of an Italian L-type BSE
(BASE) case, PrP
Sc was detected with the same neuroa-
natomical distribution, deposition pattern and staining
intensity as the HRP method. More specifically, the AP
method revealed, at both the obex and frontal cortex, a
characteristic neuropathologic trait of the Italian L-type
BSE form, i.e., the presence of PrP
Sc aggregates in the
form of plaques. Another peculiar feature described in
cattle affected by natural [30] and experimental [36] L-
type BSE is the presence of a perineuronal PrP
Sc deposi-
tion pattern which is not associated with intraneuronal
PrP
Sc deposits. This PrP
Sc pattern was also detected by
both the HRP and AP methods in the Italian L-type
BSE case in this study. It has been hypothesized that the
perineuronal PrP
Sc deposits could indicate different
PrP
Sc trafficking and propagation in L-type BSE forms
[36].
This comparative study also confirmed the reliability
of the HRP and WHE confirmatory protocols in the
diagnosis of the H-type BSE form not reported in Italy
to date. Previous investigations performed on H-type
samples obtained from other European countries
revealed that the HRP technique was successful in
detecting H-type BSE cases [30].
Under both the HRP and AP protocols, the U.S. H-
type BSE case displayed a similar PrP
Sc deposition pat-
tern of the granular, intraneuronal, and intraglial type.
At present, only the obex and not a complete brain
from an H-type BSE naturally affected cow has been
available for analysis. In the obex region of H-type BSE
cases, intraglial PrP
Sc deposition seems to be a peculiar
immunohistochemical feature, as described in cases
from Germany [30] and Sweden [37]. It is a less com-
mon feature for C- and L-type BSE cases [20,25]. Impor-
tantly, the intraglial pattern identified in a Swedish H-
type BSE case was revealed only with antibodies (F99/
97.6.1 and R145) directed against the C-terminus por-
tion of the PrP
Sc molecule [37]. In contrast, the detec-
tion of severe granular intracellular labelling in German
H-type BSE with the use of core-specific mAb 12F10
has also been reported [30].
T h eU . S .H - t y p eB S Ec a s ee x a m i n e dh e r eh a dm o r e
intense and defined PrP
Sc immunoreactivity of intra-
neuronal and intraglial distribution when tested using
the HRP as compared to the AP method. This was sur-
prising, since the AP protocol employs a ten-fold higher
concentration of the primary F99/97.6.1 antibody as
compared with the one employed by the HRP protocol.
Moreover, as compared to the HRP method, the higher
incubation temperature (37°C) at which the AP staining
protocol occurs in the Ventana NexES carousel ought to
confer a more efficient binding of the primary antibody
to the tissue antigens. However, such preferable condi-
tions in the AP method could partially be negatively
influenced by a possible prozone-like effect due to the
higher concentration of the primary antibody employed.
The formation of antibody aggregates might limit their
penetration into the cells and restrict binding to intracy-
toplasmatic antigenic sites [38]. Furthermore, it can not
be excluded that the overall shorter incubation times of
the AP protocol as compared to the HRP method might
reduce the antibody-antigen interaction. These assump-
tions aside, the discrepancy between the AP and the
HRP methods in the amount of PrP
Sc detected in the
H-type case seems more likely to be related to the dif-
ferent length of the formic acid treatment performed on
tissue sections after deparaffinization.
The HRP protocol utilizes a 25-min formic acid incu-
bation, whereas the AP protocol limits formic acid expo-
sure to 5 min. To perform immunohistochemical
analysis on formalin-fixed tissues, a demasking step in
formic acid is often used to expose antigenic sites to the
binding by antibodies [39]; this step seems to be particu-
larly critical to disclose the intracellular PrP
Sc compo-
nent in H-type BSE cases. The PrP
Sc molecule
characterizing H-type BSE probably requires prolonged
exposure to formic acid to be properly demasked in for-
malin-fixed tissues and to be revealed, mainly by
employing C-terminal antibodies, as intraneuronal and
intraglial PrP
Sc deposits.
By contrat, a shorter demasking time in formic acid, i.
e., 5 min as employed in the AP protocol, does not
seem to affect the detection of the PrP
Sc plaque depos-
i t s ,w h i c hm a yb eau n i q u ef e a t u r eo fL - t y p eB S Ec a s e s .
This finding suggests that in L-type BSE isolates the
length of incubation time in formic acid is not a very
critical step to disclose PrP
Sc deposits, perhaps indicat-
ing that L-type PrP
Sc most likely establishes weaker
interactions with formalin and can therefore be more
easily demasked than H-type PrP
Sc from formalin-fixed,
paraffin-embedded tissue sections.
In summary, we found that comparative testing of an
automated immunostaining protocol, with the use of the
Ventana NexES Autostainer System, and a manual IHC
method in the detection of PrP
Sc in various BSE cases
revealed absolute concordance in correctly identifying
BSE-positive samples and in discriminating among C-,
H- and L-type forms of BSE. Both the HRP and the AP
BSE confirmatory methods differentiated three different
phenotypes of the disease, referred to as C-, H- and L-
type forms, each appearing to be characterized by quite
distinct features of PrP
Sc deposition. Both methods
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Sc deposits as a
distinguishing feature of C-type BSE cases, whereas
intraglial and intraneuronal PrP
Sc deposition patterns
appeared as the most representative trait of H-type BSE,
and the presence of PrP
Sc deposits organized as plaques
was only detected in the L-type BSE (BASE) case.
In contrast to the IHC protocols, the WHE and the
SAFE procedures for WB methods are almost identical.
Both are, in fact, based on the enrichment of samples
according to scrapie associated fibrils (SAF) immuno-
blotting methods derived from the World Organization
for Animal Health (OIE) recommended protocol. The
minor differences between the two protocols, for exam-
ple, the use of different homogenization buffers or the
sonication step, do not seem to affect results in terms of
specificity and sensitivity to detect BSE cases. Further-
more, the fact that under both the WHE and SAFE pro-
tocols a higher amount of tissue equivalents (i.e., 10 mg)
than that normally used for medium positive cases (i.e.,
~5 0 0μg )h a dt ob el o a d e dp e rl a n ei sn o tt ob e
ascribed to the sensitivity of the methods but simply to
the need to display as best as possible the low signal
intensity known to characterize the PrP
Sc moieties of
some of the BSE cases under examination. Previous
similar attempts to maximise at WB analysis the PrP
Sc
signal intensity of slightly positive BSE samples by load-
ing even higher amounts of tissue equivalents per lane
(i.e., 38 mg) than the quantity employed here have also
been reported (27).
Our findings show that both the SAFE and WHE meth-
o d sw e r ea b l et od e t e c ta l lt h r e eB S Ef o r m s( C - ,H -a n d
L-type). The WHE and SAFE methods identified and dif-
ferentiated the specific molecular weights and glycoform
ratios associated with the three BSE forms. As regards
the H-type BSE in particular, it is noteworthy that both
the SAFE and WHE methods clearly detected this atypi-
cal form, even when an antibody such as P4 was
employed, which is known to be inferior for application
to bovine PrP compared to other antibodies such as 12B2
(29) or 6H4. The results provide reliable evidence that
the SAFE method can recognize and differentiate L-type
BSE in the current surveillance program.
The present study proved that both Italy and the U.S.
employ efficient diagnostic techniques to detect and dif-
ferentiate the three different BSE forms (C-, H- and L-
type) known to date. Furthermore, this finding suggests
that the current Italian and U.S. confirmatory methods
f o rB S Em i g h ta l s ob ea p p r o p r i a t et od i s c l o s en o v e l
forms of the disease should they ever occur.
Methods
U.S. tissues
The only C-type BSE case detected in the U.S. to date,
identified as animal B5330-7 D, was examined. This ani-
mal was an approximately 6.5-year-old, as determined
by dentition, non-ambulatory Holstein Friesian cow,
imported from Canada in 2001 and slaughtered in
Moses Lake, WA in 2003 [31] (Table 1). In accordance
with the BSE surveillance system in place at that time,
the case underwent confirmatory diagnosis by means of
histology and IHC.
Two H-type BSE cases, both U.S. born and identified
as animals B10979 and B14842, were examined. Case
B10979 was an approximately 12-year-old Brahman
cross cow that died during transport to a packing plant
[31] (Table 1). The case was first detected by rapid test-
ing (Platelia/TeSeETM ELISA BSE test, Bio-Rad, Her-
cules, CA) and later confirmed positive by WB and IHC
analysis in the U.S. and at the OIE Reference Laboratory
for BSE in Weybridge, England. Case B14842 was an
approximately 10-year-old crossbred (Bos indicus × Bos
taurus) downer cow euthanized on the owner’sf a r mb y
the herd veterinarian [16]. This case was also initially
detected by rapid testing (Platelia/TeSeETM ELISA BSE
test, Bio-Rad, Hercules, CA), then confirmed positive by
IHC and WB analysis (Table 1).
Table 1 Details of the C-, H- and L-type BSE cases examined
Case Country Age
(year)
Breed Cause of death Husbandry BSE type Tissue Tested in the study by
16193/02 Italy 5 Friesian r.s.* dairy C-type o.
# IHC
142585/03 Italy 11 Mixed c.s.† beef C-type o.
# WB
B5330-7 D USA ~ 6.5 Friesian c.s.† dairy C-type o.
# IHC, WB
B10979 USA ~ 12 Brahma cross f.s.‡ beef H-type o.
# WB
B14842 USA ~ 10 Red crossbred f.s.‡ beef H-type o.
# IHC
1088/03 Italy 15 Piedmontese f.s.‡ dairy/beef L-type o.
# WB
12966/07 Italy 14 Piedmontese f.s.‡ dairy/beef L-type o.
#, f.c.
§ IHC
* r.s., routine slaughtered
† c.s., casualty slaughtered
‡ f.s., fallen stock
# o., obex
§ f.c., frontal cortex
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Two C-type BSE cases were examined. Case 16193/02
was a 5-year-old routinely slaughtered Friesian cow and
case 142585/03 was a slaughtered 11-year-old beef cow
of mixed breed (Table 1). According to the Italian sur-
veillance programs, both cases were first detected by a
rapid screening test (Prionics Check Western, Prionics,
Zurich, Switzerland) on the brainstem, and then con-
firmed by histology, IHC and WB analysis.
Two L-type BSE (BASE) cases, identified as animal
12966/07 and animal 1088/03 [25] were examined. Both
cases were fallen stock Piedmontese cows, 14 and 15
years old respectively (Table 1), initially detected by
rapid testing and then confirmed positive by BSE confir-
matory tests.
Immunohistochemistry (IHC)
Case selection and preparation of tissue sections
The Italian C-type BSE case (16193/02), U.S. C-type BSE
case (B5330-7 D), Italian L-type (BASE) case (12966/07)
and U.S. H-type case (B14842) were examined by IHC
under both the HRP and the AP protocols. Obex sec-
tions for all cases and additional sections of the frontal
cortex of the L-type case were tested (Table 1).
Serial sections were cut and numbered consecutively
in order to test tissue sections, alternating between the
AP protocol and the HRP method. Three slides of each
tissue sample selected for the study were tested under
the HRP protocol: two sections were incubated with the
primary antibody; one, on which the primary antibody
was omitted, was used as an internal control. Two slides
of each tissue sample underwent IHC according to the
AP protocol, and the primary antibody was applied to
both of them.
The IHC staining comparison study was performed at
the National Veterinary Services Laboratories (NVSL) in
Ames, IA.
AP protocol
Tissues selected for examination were fixed in 10% buf-
fered formalin, embedded in paraffin blocks, sectioned
at 5 μm and mounted onto charged glass slides (Fisher
Superfrost Plus, Fisher Scientific, Hampton, NH). The
slides were air dried for a minimum of 3 h, put in an
oven for 15 min at 80°C, deparaffinized in xylene, and
rehydrated in graded alcohols, followed by distilled H2O.
They were then incubated in 95% formic acid for 5 min,
followed by three washes (2 min each) in Tris Buffer pH
7.5 and a 1-min wash in laboratory quality water. The
slides were immersed in an antigen retrieval citrate buf-
fer, pH 6 (DAKO™Target Retrieval Solution, Dako
North America Inc., Carpinteria, CA) and placed in a
commercially available antigen retrieval device (Biocare
Medical, Concord, CA) for 30 min at 121°C. After the
slides were allowed to cool to room temperature (RT),
they were stained using an automated immunostainer
(NexES IHC module, Ventana Medical Systems Inc.,
Tucson, AZ), previously filled with the PrP-specific F99/
97.6.1 antibody (epitope QYQRES, aa 220-225 of the
ovine PrP, 10 μg/ml dilution; VMRD Inc., Pullman,
WA) [40], APK wash solution (Ventana Medical Sys-
tems Inc.) and liquid coverslip bottles (Dako North
America Inc.). As suggested by the manufacturer, all
incubations were performed on a Ventana NexES plat-
form at 37°C following the alkaline phosphatase red par-
affin protocols. The first step associated with the
autostainer included incubation of sections with the
F99/97.6.1 anti-PrP antibody for 32 min, rinsing and
application of coverslip solution. The following steps
were performed employing reagents provided by the
A l k a l i n eP h o s p h a t a s eB a s i cR e dK i t( V e n t a n aM e d i c a l
Systems Inc.) and involved incubation of the slides with
a biotinylated goat antimouse IgG for 8 min, application
of an avidin-alkaline phosphatase complex for 12 min,
followed by incubation with an Enhancer reagent for a 4
min. Naphthol was used as substrate for the reaction
and applied for 8 min together with Fast Red A, used as
chromogen. Incubation with Fast Red B, used as second
chromogen, followed for 8 min. The sections were sub-
sequently counterstained with Gill’s hematoxylin (Ven-
tana Medical Systems Inc.) for 4 min and then post-
counterstained with bluing reagent (Ventana Medical
Systems Inc.) for 2 min. At the end of the process, the
slides were removed from the automated stainer and
dipped in warm tap water with 2-3 drops of liquid dish-
washing detergent added (Non Ultra Dish Liquid, Origi-
nal Scent, Dawn. Procter & Gamble, Cincinnati, OH).
After washes in tap water, the sections were dehydrated
in ethyl alcohol and xylene and then coverslipped with a
permanent mounting medium.
Test slides were examined by light microscopy and
classified as positive or negative for PrP
Sc immunoreac-
tivity. PrP
Sc immunoreactivity was defined as pink to
red staining; slides identified as negative for PrP
Sc con-
tained only counterstaining which appeared blue. As
positive controls, slides from the obex tissue of a scrapie
positive sheep, obtained from the NVSL, and from the
brainstem and the frontal cortex, respectively, of two
experimentally infected TME positive cows, provided by
the National Animal Disease Center (NADC), were
employed. Obex tissue sectio n so fa nI t a l i a nB S En e g a -
tive cow were utilized as negative controls.
HRP protocol
The Italian samples selected for the study were forma-
lin-fixed and then treated for decontamination with 98%
formic acid for 1 h before being embedded in paraffin
blocks. Under the HRP protocol, sections were cut 5 μm
thick for each sample, placed onto charged glass slides,
drained, air dried for 10 min and then incubated at 37°
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steps: the first two in xylene, the next two in absolute
ethyl alcohol. The slides were then rinsed and immersed
in 98% formic acid for 25 min. After washing in distilled
water, the rack of slides was put into a container filled
with fresh epitope demasking solution (citrate buffer pH
6.1) with anti-bump glass beads at the bottom. The sec-
tions were then autoclaved for 30 min at 121°C. Endo-
genous peroxidase activity was blocked using 3%
hydrogen peroxide in methanol for 20 min at RT. To
block non-specific tissue antigens, the sections were
incubated with 5% horse blocking serum for 20 min at
RT, then incubated for 1 h at RT with the primary
monoclonal antibody (MAb) F99/97.6.1 (epitope
QYQRES, aa 220-225 of the ovine PrP, 1 μg/ml dilution;
VMRD Inc.) [40]. After rinsing, a biotinylated goat anti-
mouse secondary antibody (1:200 dilution; Vectastain
ABC kit, Vector Laboratories, Burlingame, CA) was
applied to the tissue sections for 30 min at RT, followed
by the avidin-biotin-peroxidase complex (Vectastain
ABC kit, Vector Laboratories) for a minimum of 30
min. PrP
Sc immunoreactivity was visualized using 3-3’-
diaminobenzidine (Dakocytomation, Carpinteria, CA) as
chromogen; the sections were then counterstained with
Meyer’s hematoxylin, dehydrated in ethyl alcohol and
xylene and coverslipped. PrP
Sc immunoreactivity
appeared from light to dark brown, whereas slides iden-
tified as negative for PrP
Sc staining contained only coun-
terstaining which appeared blue. Positive and negative
tissue controls for the HRP protocol were identical to
the aforementioned controls used for the AP protocol.
Assessment of PrP
Sc immunoreactivity
For the C- and L-type BSE cases, the obex was sampled
at the neuroanatomical level including the following
nuclei: NST; DMNV; NSTV; the nucleus of the hypo-
glossal nerve; the olivary nucleus; the reticular forma-
tion. This allowed for the identification of PrP
Sc
deposition and distribution.
For the L-type BSE (BASE) case, an area of frontal
cortex was also examined.
Assessment of PrP
Sc immunoreactivity was based on
neuroanatomical location, morphology and intensity (0,
+ ,++ ,+++ )w h e r e0d e n o t e sn oP r P
Sc,+d e n o t e s
mild intensity, + + denotes moderate intensity, and + +
+ denotes marked intensity [20]. This assessment of
PrP
Sc intensity is subjective.
Western blot
Frozen obex samples from the Italian C-type BSE case
(142585/03), U.S. C-type BSE case (B5330-7 D), Italian
L-type (BASE) case (1088/03) and U.S. H-type case
(B10979) and CNS tissue from a healthy bovine, used as
negative control, were tested under both the WHE and
the SAFE WB protocols (Table 1).
A portion of the Italian C- and L-type BSE cases was
shipped to the Agricultural Research Service (ARS)
Laboratories of the NADC, Ames, Iowa, where the WB
comparison study was performed.
SAFE protocol
The OIE-recommended SAF-Immunoblot method [41]
was used with minor modifications. Tissue homogenates
(10% [w/v]) in 10 mM Tris, pH 7.5, containing 5 mM
MgCl2 were prepared. The homogenates were sonicated
f o r3 0si na ni c eb a t h .B e n z o n a s en u c l e a s e( 1 0 0U / m l ;
Novagen, Merck KGaA, Darmstadt, Germany) was added
to the homogenates and they were incubated for 1 h at
37°C while shaking. An equal volume of 20% (w/v) sarco-
s y li n1 0m MT r i s ,p H7 . 5a n d1m Md i t h i o t r e i t h o l
(DTT) was added to each homogenate, vortexed for 1
min every 10 min for a total of 30 min at RT. The homo-
genates were transferred to polyallomer tubes and centri-
fuged at 20,000 g for 25 min at 10°C. Supernatants were
collected and centrifuged again at 200,000 g for 55 min at
10°C. The resultant supernatants were discarded. The
pellets were resuspended in sterile, distilled water (1 μl/
mg tissue equivalent) and sonicated until suspended. The
samples were treated with PK (40 μg/ml) by incubation
at 37°C for 1 h with agitation. Phenylmethylsulphonyl
fluoride (PMSF) was added to a final concentration of 5
mM, and the samples were incubated on ice for 15 min.
T h ev o l u m ew a sb r o u g h tu pt o5 0 0μl with water and
centrifuged at 200,000 g for 1 h at 10°C. Supernatants
were discarded and the pellets were resuspended in
sodium dodecyl sulphate polyacrylamide gel electrophor-
esis (SDS-PAGE) sample buffer (Invitrogen, Carlsbad,
CA).
WHE protocol
Samples were extracted by the WHE method pre-
viously reported [42]. Briefly, 10% (w/v) brainstem tis-
sues were homogenized in sarcosyl-Tris buffered saline
solution, pH 7.5. The homogenates were clarified by
centrifugation at 22,000 g for 20 min at 10°C and the
supernatants were incubated with PK (40 μg/ml) for 1
h at 37°C under continuous shaking. Digestion was
stopped by adding 10 μl of PMSF 100 mM to the sam-
ples. After ultracentrifugation (Ultracentrifuge Optima
TLX, Rotor TLA 110, Beckman Coulter, Fullerton, CA)
at 215,000 g for 1 h at 10°C, the supernatants were dis-
carded and pellets were resuspended in Laemmli
buffer.
Western blot analysis
The samples extracted by the two methods were boiled
for 10 min at 99°C, then separated by SDS-PAGE on 4-
12% minigels (Invitrogen) and transferred onto polyviny-
lidene difluoride (PVDF) membranes (Immobilon-P,
Millipore, Billerica, MA). Blots were blocked with PVDF
blocking buffer (Invitrogen) for 1 h at RT, and blotted
bovine PrP was detected with 6H4 (0.2 μg/ml; Prionics)
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many) [28] monoclonal antibodies, respectively. After
three washes with Tris buffered saline Tween 20 (TBST)
(Invitrogen), the blots were incubated for 30 min at RT
with a biotinylated sheep anti-mouse antibody (GE-
Healthcare Ltd., St. Giles, UK). After another round of
washes, streptavidin-horseradish peroxidase conjugate
(GE-Healthcare Ltd.) incubation was done. Membranes
were developed using ECL Plus chemiluminescent sub-
strate (GE-Healthcare Ltd.) onto Hyperfilm ECL (GE-
Healthcare Ltd.). The photographic films were then
recorded using the UVI-prochemi gel documentation
system (Uvitec, Cambridge, UK).
P4/6H4 mAbs ratio evaluation and glycoform analysis
The ratio between P4 and 6H4 mAbs was calculated by
examining the films at equal time exposure, taking into
account only the H-type sample signals. Samples were
run three times and the films were analyzed using UVI-
prochemi software (Uvitec).
A glycoform analysis was performed to better deter-
mine whether the glycoform pattern of the three PrP
Sc
of the different BSE strains was detected by both extrac-
tion protocols. The samples were examined in three
runs to evaluate the variability of the methods. Signals
detected with mAb 6H4 were examined using UVI-pro-
chemi software (Uvitec) and the values obtained for the
di-glycosylated, mono-glycosylated and un-glycosylated
bands were plotted as a graph.
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